MannKind Corporation
Nintedanib DPI (MNKD-201)
idiopathic pulmonary fibrosis
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for Nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Nintedanib DPI INFLO-1 Phase 1b topline data, we believe we are well ‑ positioned to drive long ‑ term value for patients, providers and shareholders. Our team’s hard work over the last several years is culminating in significant milestones”